
    
      This is a randomized, double-blind, placebo-controlled single and multiple ascending dose
      study to evaluate the ocular tolerability, safety, and pharmacokinetics of R348 administered
      in patients with mild to moderate keratoconjunctivitis sicca (KCS).
    
  